32 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Trehalose- and glucose-derived glycoamphiphiles: small-molecule and nanoparticle Toll-like receptor 4 (TLR4) modulators.
University of Sevilla
Development ofaGlcN(1¿1)aMan-based lipid A mimetics as a novel class of potent Toll-like receptor 4 agonists.
University of Natural Resources and Life Sciences
Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening.
Blood Transfusion Centre of Slovenia
Novel endotoxin-sequestering compounds with terephthalaldehyde-bis-guanylhydrazone scaffolds.
University of Kansas
Development ofß-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics.
University of Colorado At Boulder
The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics.
Glaxosmithkline
Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.
Eisai Research Institute
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).
Biocon Bristol Myers Squibb Research Center (Bbrc)
Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective.
Shenyang Pharmaceutical University
Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy.
Tsinghua University
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an
Novartis Institutes For Biomedical Research
Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and In Vivo Activity.
University of Milano-Bicocca
Synthesis, activity and mechanism for double-ring conjugated enones.
Hainan Normal University
Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.
University of Kansas
Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
University of Siena
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
Princ
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Genomics Institute of The Novartis Research Foundation
Design and Catalyzed Activation of Tak-242 Prodrugs for Localized Inhibition of TLR4-Induced Inflammation.
Baylor University
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
Linear and Rationally Designed Stapled Peptides Abrogate TLR4 Pathway and Relieve Inflammatory Symptoms in Rheumatoid Arthritis Rat Model.
Ajou University
Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury.
Wenzhou Medical University
Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout.
Soochow University
Discovery of novel small molecule TLR4 inhibitors as potent anti-inflammatory agents.
School of Pharmaceutical Sciences
High Mobility Group Box-1 (HMGb1): Current Wisdom and Advancement as a Potential Drug Target.
The Feinstein Institute For Medical Research
Structure-Activity Relationship in Monosaccharide-Based Toll-Like Receptor 4 (TLR4) Antagonists.
University of Milano-Bicocca
Structure-Activity Relationship Studies of Pyrimido[5,4-b]indoles as Selective Toll-Like Receptor 4 Ligands.
University of California
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University of Colorado Boulder
